SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3032That's ok. I appreciate the message. All is forgiven. I think these smallCuttingEdge Bio-7/3/2020
3031What does the phrase, “strict-term” mean?DewDiligence_on_SI-7/2/2020
3030clinicaltrials.gov Smart trial setup for phase 3 - prevention. Biotechwantabe-7/2/2020
3029I have to apologize here, and I am apologizing! Kevzara did not show efficacy inMiljenko Zuanic-7/2/2020
3028They had They time to prepare NY manufacturing facility, for covid. For Dupi anMiljenko Zuanic-7/1/2020
3027If other parties are involved in order to meet worldwide demand for a successfulCuttingEdge Bio-6/30/2020
3026All I want is to be rational with COVID. World needs good-effective treatment oMiljenko Zuanic-6/30/2020
3025Everything I read gives me a bit of confidence that regeneron would have best mABiotechwantabe-6/29/2020
3024From before we know that BARDA/NIH is sponsoring/collaborating on Kevzara P2/3 tMiljenko Zuanic-6/29/2020
3023Regeneron Pharmaceuticals, Inc USAProduct Name: SarilumabDescription: Kevzara (Biotechwantabe-6/29/2020
3022Thanks for sharing although I don't think it's known but there must be sFelix B-6/29/2020
3021BARDA financing is (so far), $82M for R&D and $85M for P1/2: twitter.com meMiljenko Zuanic-6/29/2020
3020I don't think REGN can price any treatment right, either upset public or walFelix B-6/29/2020
3019Remd at $2-3K per treatman (with very limited benefit) is prised exceptionally wMiljenko Zuanic-6/29/2020
3018verywellhealth.com EGFR and Squamous Cell Carcinoma of the Lungs The EGFR pathwBiotechwantabe16/27/2020
3017R.I.P ABBV's Abicipar (DARPin) for wet AMD: investorshub.advfn.comDewDiligence_on_SI16/26/2020
3016Regeneron plans to begin a clinical trial with EGFRxCD28 (REGN7075) and Libtayo Biotechwantabe16/25/2020
3015Adjuvant/neoadjuvant sSCC is much bigger market.Miljenko Zuanic-6/25/2020
3014FDA approves Keytruda monotherapy in cSCC: businesswire.comDewDiligence_on_SI-6/25/2020
3013Will see how much will REGN charge BARDA for 2Q?Miljenko Zuanic-6/25/2020
3012Wow, unexpected and I am am not sure how to interpret this...?Felix B-6/24/2020
3011Pretty sure BARDA funded R&D just as they did for Ebola and that's why IFelix B-6/24/2020
3010finance.yahoo.comBiotechwantabe-6/24/2020
3009Flu patent. freepatentsonline.com Good background description of patent populaBiotechwantabe-6/24/2020
3008<I Assume price will be dependent on how well it works for treatment. “Based Miljenko Zuanic16/24/2020
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News